Back to search

Peptide record

TPDB40963

LJP-4 Anticancer standard
5 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB40963
LJP-4
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 5-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
EGHGF
Physicochemical Analysis
C24H31N7O8
ARNDCQILKMPSTWYV
G
545.55
5.13
1
1
1
-1
1.87
-0.940
0.00
Mammalian: 1 hour Yeast: 30 min E.coli: >10 hour
0
0.00
0
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
1
E
0
Q
2
G
1
H
0
I
0
L
0
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 1 Q: 0 G: 2 H: 1 I: 0 L: 0 K: 0 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
5
C24H31N7O8
545.55
5.13
-1
1.87
-0.940
Free
L
Linear
Free
Anticancer
Laminaria japonica
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 0.62 ± 0.07 mM
Anticancer
0.62

Target

Liver Cancer
Huh-7
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 0.65 ± 0.07 mM
Anticancer
0.65

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 3 Activity

Activity

IC50
IC50 = 0.68 ± 0.07 mM
Anticancer
0.68

Target

Liver Cancer
H-22
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022